Head turning deals in precision medicine typically result in competitor companies analyzing every move prior to their peer’s deal and then trying to make quick ingredient fixes to their own model to try to achieve the same, picking and choosing which changes most suit their investors’ previous experience, preconceived notions and risk tolerance. But in this complex environment, more companies are choosing wrong over right, and no one single ingredient change leads to success. What is the winning recipe? Learn from success stories in precision medicine deals, from platform-based to data-based to lab service based that resulted in significant return to investors from those directly involved in the deals. Attendees will also hear about lessons learned from the journey and guidance for all investors on how to navigate the precision medicine space in the future.